Skye Bioscience (SKYE) Total Liabilities (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Total Liabilities of $10.4 million for Q1 2026, up 87.72% year-over-year from $5.5 million in Q1 2025, and up 25.52% quarter-over-quarter from $8.3 million in Q4 2025.
Skye Bioscience (SKYE) Total Liabilities (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Total Liabilities for 15 consecutive years, with $10.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 87.72% year-over-year to $10.4 million; the TTM figure through Mar 2026 stood at $10.4 million (up 87.72% YoY), while the FY2025 annual figure was $8.3 million, up 79.73% from the prior year.
- Total Liabilities improved to $10.4 million in Q1 2026 per SKYE's latest filing, from $8.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $16.0 million in Q1 2024 and bottomed at $4.2 million in Q1 2022.
- Historically, Total Liabilities has averaged $9.2 million across 5 years, with a median of $8.5 million in 2025.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 203.67% — and 2024, when it plunged 67.23%.
- Skye Bioscience's Total Liabilities stood at $12.1 million in 2022, then grew by 16.12% to $14.1 million in 2023, then sank by 67.23% to $4.6 million in 2024, then jumped by 79.73% to $8.3 million in 2025, then increased by 25.52% to $10.4 million in 2026.
- Business Quant data shows SKYE's Total Liabilities at $10.4 million in Q1 2026, $8.3 million in Q4 2025, and $8.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 10.03 Bn |
| 10 | Skye Bioscience | 10.71 Mn | 10.71 Mn | - | 11.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.40 Mn |
| Dec 31, 2025 | 8.29 Mn |
| Sep 30, 2025 | 8.49 Mn |
| Jun 30, 2025 | 8.48 Mn |
| Mar 31, 2025 | 5.54 Mn |
| Dec 31, 2024 | 4.61 Mn |
| Sep 30, 2024 | 5.73 Mn |
| Jun 30, 2024 | 14.45 Mn |
| Mar 31, 2024 | 15.95 Mn |
| Dec 31, 2023 | 14.07 Mn |
| Sep 30, 2023 | 13.91 Mn |
| Jun 30, 2023 | 10.03 Mn |
| Mar 31, 2023 | 9.37 Mn |
| Dec 31, 2022 | 12.12 Mn |
| Sep 30, 2022 | 6.15 Mn |
| Jun 30, 2022 | 5.27 Mn |
| Mar 31, 2022 | 4.24 Mn |
| Dec 31, 2021 | 3.99 Mn |
| Sep 30, 2021 | 3.42 Mn |
| Jun 30, 2021 | 3.22 Mn |